A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-08-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-1248PMID 27542767PMCID PMC5621377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting CDK4 and CDK6: From Discovery to Therapy.

  2016cited by this paper
• The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

  2015cited by this paper
• Phase 2 trial of the cyclin‐dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein‐expressing germ cell tumors

  2015cited by this paper
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cited by this paper
• Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

  2014cited by this paper
• Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

  2013cited by this paper
• Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

  2013influential reference
• Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

  2013influential reference
• CDK4: A Key Player in the Cell Cycle, Development, and Cancer.

  2012cited by this paper
• Critical aspects of the Bayesian approach to phase I cancer trials

  2008cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Cyclin-dependent kinase pathways as targets for cancer treatment.

  2006cited by this paper
• Cyclin D-dependent kinases, INK4 inhibitors and cancer.

  2002cited by this paper
• Update on the therapeutic potential of PDE4 inhibitors

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Role of the p16 tumor suppressor gene in cancer.

  1998cited by this paper

• Optimizing ribociclib dosing in breast cancer with brain metastasis patients using a physiologically based pharmacokinetic model

  2026influential citation
• Bacterial ubiquitin ligase engineered for small molecule and protein target identification

  2026cites this paper
• A phase I/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent/relapsed high-grade glioma

  2026cites this paper
• Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors.

  2025cites this paper
• CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.

  2025cites this paper
• Rethinking Ribociclib Dosage and Use in the Era of Patient-Centered Oncology-When Less Is More.

  2025cites this paper
• A functional map of CDK-drug interactions at single amino acid resolution

  2025cites this paper
• Targeting CDK4 and CDK6 in hormone-dependent cancers.

  2025cites this paper
• Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial

  2025influential citation
• Targeting CDK4/6 in breast cancer

  2025cites this paper
• Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment

  2025cites this paper
• Temperature-dependent solubilization and thermodynamic characteristics of ribociclib in varied {PEG 400 + water} combinations

  2025influential citation
• Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward

  2025cites this paper
• Adverse Event Profiles of CDK4/6 inhibitors: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.

  2025cites this paper
• Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): Emerging strategies for cancer therapy.

  2025cites this paper
• Binding Mechanism of Inhibitors to CDK6 Deciphered by Multiple Independent Molecular Dynamics Simulations and Free Energy Predictions

  2025influential citation
• Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors

  2025cites this paper
• Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception.

  2025cites this paper
• A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors

  2025cites this paper
• Interstitial lung disease following combined CDK4/6 inhibitor therapy and radiotherapy in advanced breast cancer: a case report

  2025cites this paper
• Ribociblib in Sequential Combination with Doxorubicin in Anthracycline-Naive Advanced Soft Tissue Sarcomas: Results of a Dose-Finding Phase 1B Study.

  2025cites this paper
• FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Dosages for First-In-Human Trials.

  2025cites this paper
• First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

  2025cites this paper
• A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer

  2025cites this paper
• Bacterial ubiquitin ligase engineered for small molecule and protein target identification

  2025cites this paper
• A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System

  2025cites this paper
• Cardiovascular toxicity of cyclin-dependent kinase 4 and 6 inhibitors

  2025cites this paper
• Mechanisms of action for FDA-approved drugs targeting breast cancer

  2025cites this paper
• Mechanisms and Management of Arrhythmias in Cancer Patients

  2025cites this paper
• Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer

  2025cites this paper
• Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications

  2024cites this paper
• Cardiovascular complications of ribociclib in breast cancer patients.

  2024cites this paper
• Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer

  2024cites this paper
• Wnt/β-catenin signaling pathway in the tumor progression of adrenocortical carcinoma

  2024cites this paper
• Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer.

  2024cites this paper
• CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety.

  2024cites this paper
• Validation of Core Ingredients and Molecular Mechanism of Cinobufotalin Injection Against Liver Cancer

  2024cites this paper
• Promises of natural products as clinical applications for cancer.

  2024cites this paper
• Cell cycle dysregulation in cancer.

  2024cites this paper
• Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models.

  2024cites this paper
• Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis

  2024cites this paper
• In silico identification of novel CDK4 inhibitors for retinoblastoma.

  2024cites this paper
• Novel pharmacotherapies for the treatment of liposarcoma: a comprehensive update

  2024cites this paper
• Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2– advanced breast cancer

  2024cites this paper
• Molecular characteristics and systemic treatment options of liposarcoma: A systematic review.

  2024cites this paper
• BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair

  2024cites this paper
• RETRACTED ARTICLE: Combined Ribociclib and NU7026 administration enhances radio-sensitivity by inhibiting DNA repair in prostate cancer

  2024cites this paper
• A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors

  2024influential citation
• Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.

  2024cites this paper
• An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies

  2024cites this paper
• Pharmacodynamic characteristics, safety profile, and interactions of CDK4/6 inhibitors (CDK4/6i) in HR+/HER2– advanced/metastatic breast cancer

  2024cites this paper
• Loss of p16 Immunoexpression and Deletions of CDKN2A in the Progression of Extramammary Paget Disease: An Immunohistochemical and Genetic Study of 24 Invasive/Metastatic Cases

  2024cites this paper
• Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models

  2024cites this paper
• Optimized Ribociclib nanostructured lipid carrier for the amelioration of skin cancer: Inferences from ex-vivo skin permeation and dermatokinetic studies

  2024cites this paper
• The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment

  2023cites this paper
• ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma

  2023cites this paper
• Binding patterns of derivatives of fisetin and chrysin to the enzyme complex cyclin-dependent kinase 6/cyclin D

  2023cites this paper
• Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

  2023cites this paper
• Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study

  2023cites this paper
• Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer

  2023cites this paper
• The CDK4/6 Inhibitors Biomarker Landscape: the most Relevant Biomarkers of Response or Resistance for Further Research and Potential Clinical Utility.

  2023cites this paper
• Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment

  2023cites this paper
• Ribociclib-induced visual hallucination in a patient with metastatic breast cancer

  2023cites this paper
• Quantitative Assessment of Ribociclib Exposure–Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer

  2023cites this paper
• E3 ligase MG53 suppresses tumor growth by degrading cyclin D1

  2023cites this paper
• ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous Melanoma

  2023cites this paper
• Ribociclib-Induced Acute Kidney Injury in Patients with Advanced-Stage Breast Cancer: A case series and literature review

  2023cites this paper
• Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

  2023cites this paper
• Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials

  2023cites this paper
• Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy

  2023cites this paper
• A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.

  2023cites this paper
• Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer

  2023cites this paper
• Anti-cancer drug molecules targeting cancer cell cycle and proliferation.

  2023cites this paper
• CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review

  2023cites this paper
• Developing SHP2-based combination therapy for KRAS-amplified cancer

  2023cites this paper
• MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.

  2023cites this paper
• Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines

  2023cites this paper
• An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

  2022cites this paper
• Genomic Features of Organ-Specific Metastases in Lung Adenocarcinoma

  2022cites this paper
• Breast Cancer and the Cardiovascular Disease: A Narrative Review

  2022cites this paper
• CDK 4/6 inhibitors for the treatment of meningioma

  2022cites this paper
• Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications.

  2022cites this paper
• Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

  2022cites this paper
• Ribociclib-Induced Acute Pancreatitis in Metastatic Breast Cancer

  2022cites this paper
• Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma

  2022cites this paper
• Established and Experimental Systemic Treatment Options for Advanced Liposarcoma

  2022cites this paper
• New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies

  2022cites this paper
• A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis

  2022cites this paper
• Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells

  2022cites this paper
• Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report

  2022cites this paper
• Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

  2022cites this paper
• Targeting CDK4 and CDK6 in cancer

  2022cites this paper
• Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials

  2022cites this paper
• Solubilization of a novel antitumor drug ribociclib in water and ten different organic solvents at different temperatures

  2022cites this paper
• Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy.

  2022cites this paper
• A phase Ib/II study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer.

  2022cites this paper
• Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment

  2022cites this paper
• Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.

  2022cites this paper
• Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database

  2022cites this paper
• Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges

  2022cites this paper